Pathology and Therapies in Brain Tumor
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 20 May 2026 | Viewed by 6
Special Issue Editor
2. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Interests: hepatocyte growth factor and its receptor c-Met; EGFR and EGFRvIII; glioblastoma; chemotherapeutics; radiation therapy; osmotic pump-based therapeutic delivery; nanoparticles; Mir-RNAs
Special Issue Information
Dear Colleagues,
Brain tumors are a highly heterogeneous group of neoplasms encompassing primary tumors originating from neural or glial cells (e.g., gliomas, meningiomas). Brain tumor therapies remain a significant challenge in oncology due to their complex pathophysiology. In recent years, remarkable progress has been made in unraveling the molecular pathology of brain tumors. However, critical barriers persist regarding the treatment of tumors—there is an urgent need for more innovative solutions to advance brain tumor treatment.
This Special Issue focuses on developing preclinical models to treat brain cancer via molecular-based therapies. It also focuses on how to deliver therapeutics into brain cancer in experimental animals. We strongly encourage the submission of original research articles and review papers that delve into these topics, as well as discussions on future directions in brain tumor research.
All accepted papers will be published on an ongoing basis in full open access format, ensuring the broad visibility and accessibility of critical findings.
We look forward to receiving your contributions that drive progress in this vital field.
Dr. Bachuchu Lal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain tumor
- gliomas
- target treatment
- pathogenesis
- animal models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
